Auto-injectors Market Size & Share, by Product Type (Disposable, Reusable); Disease Indication (Rheumatoid Arthritis, Multiple Sclerosis, Diabetes, Anaphylaxis); End-Use (Home Care Settings, Hospitals & Clinics, Ambulatory Surgical Centers); Technology (Manual, Automatic); Route of Administration (Subcutaneous, Intramuscular) - Global Supply & Demand Analysis, Growth Forecasts, Statistics Report 2024-2036

  • Report ID: 3511
  • Published Date: Nov 14, 2023
  • Report Format: PDF, PPT

Global Market Size, Forecast, and Trend Highlights Over 2024-2036

Auto-injectors Market size is poised to reach USD 33 Billion by the end of 2036, growing at a CAGR of 17% during the forecast period, i.e., 2024-2036. In the year 2023, the industry size of auto-injectors was USD 10 Billion. The reason behind the growth is impelled by the rising cases of rheumatoid arthritis. Hand disabilities can make it more difficult for individuals with rheumatoid arthritis (RA) to use syringes to give medication as part of their therapy therefore, auto-injectors could potentially mitigate this problem as by using them patients can administer etanercept a medicine used to treat rheumatoid arthritis on their own, in the comfort of their own homes, using an auto-injection pen-like device. Globally, more than 17 million cases of rheumatoid arthritis were reported in 2020.

The growing government initiatives to increase awareness are believed to fuel the market growth. For instance, on June 2023 the Medicines and Healthcare Products Regulatory Agency (MHRA), in collaboration with allergy awareness advocates, released new guidelines outlining the most recent safety recommendations for what to do in the event of anaphylaxis and offered guidance on how to use adrenaline auto-injectors.

Auto-injectors Market Overview (1)
Get more information on this report: Request Free Sample PDF

Auto-injectors Market: Key Insights

Base Year


Forecast Year




Base Year Market Size (2023)

~ USD 10 Billion

Forecast Year Market Size (2036)

~ USD 33 Billion

Regional Scope

  • North America (U.S., and Canada)
  • Latin America (Mexico, Argentina, Rest of Latin America)
  • Asia-Pacific (Japan, China, India, Indonesia, Malaysia, Australia, Rest of Asia-Pacific)
  • Europe (U.K., Germany, France, Italy, Spain, Russia, NORDIC, Rest of Europe)
  • Middle East and Africa (Israel, GCC North Africa, South Africa, Rest of the Middle East and Africa)
Get more information on this report: Request Free Sample PDF

Auto-injectors Sector: Growth Drivers and Challenges


Growth Drivers

  • Growing Popularity of Biosimilars and Biologics- Biological pharmaceuticals and biosimilar medications are generally brittle proteins that require the use of auto-injectors to raise the medication's therapeutic value.
  • Surging Phobia from Needles- Many people are afraid of needles and the agony that comes with injection sites therefore, for certain patients, using a small needle auto-injector can make administering medication easier which is intended to simplify, facilitate, and ease the injection process.
  • Increasing Regulatory Approvals- For instance, in May 2023, the U.S. Food and Drug Administration (FDA) approved the Cyltezo Pen which is recommended for patients who might like using an auto-injector to provide the medication required to control several chronic inflammatory illnesses.
  • Spiking Prevalence of Diabetes- Insulin jet injectors are a reliable method of delivering insulin that may even be more efficient than others for diabetics without the need for a needle by using a high-pressure air mechanism to eject a tiny mist of insulin through the skin. According to estimates, diabetes affected over 535 million people globally in 2021, and by 2045, that figure is predicted to rise to more than 780 million people.
  • Increasing Usage in Pediatric Population- A major development in pediatric medicine is the availability of an epinephrine auto-injector designed specifically for the needs of infants and toddlers that has grown in popularity for the prehospital management of severe allergic responses.


  • Presence of Alternative Modes for Administrating Drugs - Medication administration techniques vary widely and are frequently categorized based on the site of administration, such as intravenous or oral out of which the oral administration is the recommended method for most prescribed medications. This, as a result, may limit the demand for auto-injectors.
  • Growing Fear of Needles May Limit the Adoption of Auto-injectors
  • Creating an auto-injector that can accommodate varied injection rates and volumes while maintaining safety and accuracy is a challenge.

Auto-injectors Segmentation

Disease Indication (Rheumatoid Arthritis, Multiple Sclerosis, Diabetes, Anaphylaxis)

The anaphylaxis segment in the auto-injectors market is estimated to gain a robust revenue share of 35% in the coming years owing to the rising number of people with food allergies. Globally, food allergies are becoming more common owing to various causes, including, obesity, vitamin D, exposure to ambient chemicals, gut microbiota makeup, cleanliness and lack of exposure to microbiological factors, and environmental chemical exposure. Moreover, experts believe that the number of people with food allergies is expanding, as foods that are generally considered nutritious can be poisonous to someone with allergies. 

For certain people, a food allergy can cause anaphylaxis, a severe allergic reaction that happens when the immune system misinterprets a meal or substance as hazardous. This reaction can happen minutes after exposure. Additionally, anaphylaxis is a serious allergic reaction that can be fatal and, if treated right away, may usually be controlled. All these factors are expected to drive the demand for auto-injectors as they are recognized as emergency anaphylaxis therapy. For instance, more than 10 million Americans suffered from food allergies as of 2021.

Product Type (Disposable, Reusable)

Auto-injectors market from the disposable segment is set to garner a notable share. Disposable auto-injectors for prefilled syringes are simple to use and meant for patients to administer fixed-dose injections subcutaneously. Moreover, more than 60% of single-use auto-injectors are disposable and the market is expected to grow owing to the increasing adoption of innovative technologies.

Our in-depth analysis of the global market includes the following segments:

          Product Type

  • Disposable
  • Reusable

          Disease Indication

  • Rheumatoid Arthritis
  •  Multiple Sclerosis
  • Diabetes
  •  Anaphylaxis


  • Home Care Settings
  •  Hospitals & Clinics
  • Ambulatory Surgical Centers


  • Manual
  • Automatic

          Route of Administration

  • Subcutaneous
  • Intramuscular

Want to customize this research report as per your requirements? Our research team will cover the information you require to help you take effective business decisions.

Customize this Report

Auto-injectors Industry- Regional Synopsis

North American Market Forecast

Auto-injectors market in North America is predicted to account for the largest share of 45% by 2036 impelled by the rising investment in the healthcare sector. In 2021, healthcare spending made up more than 18% of the country's GDP. The region's advanced healthcare infrastructure encourages more people with a variety of medical problems to use auto-injectors. Recent developments and competitive strategies such as market expansion, mergers and acquisitions, and product launches have been considered to depict a competitive landscape in the market. For instance, in 2023, Coherus BioSciences, Inc. a leading global biosimilar company announced that UDENYCA, a single-dose prefilled auto-injector package, is available for commercial sale which is given the day following chemotherapy to reduce the risk of infection.

APAC Market Statistics

The APAC Auto-injectors market is estimated to be the second largest, during the forecast timeframe led by rising advancement in medical technologies. The 'Make in India' campaign of the Indian government promotes the production of medical devices in the country which has given rise to several advancements and will therefore cause the demand for more sophisticated auto-injectors to skyrocket in the upcoming years that are significant class of medical devices that are self-injectable and capable of delivering medications intramuscularly or subcutaneously.

Research Nester
Auto-injectors Market Region
Get more information on this report: Request Free Sample PDF

Companies Dominating the Auto-injectors Landscape

    • Eli Lilly and Company
      • Company Overview
      • Business Strategy
      • Key Product Offerings
      • Financial Performance
      • Key Performance Indicators
      • Risk Analysis
      • Recent Development
      • Regional Presence
      • SWOT Analysis
    • Scandinavian Health Ltd.
    • AbbVie, Inc.
    • Amgen
    • Owen Mumford
    • Ypsomed
    • Biogen Idec
    • Mylan N.V.
    • Pfizer, Inc.
    •  Sanofi
    • Stevanato Group
    • Teva Pharmaceutical


In The News

  • Eli Lilly and Company announced that it has received approval from the U.S. Food and Drug Administration (FDA) for Mounjaro (tirzepatide) injection a single molecule that activates the body's receptors for GIP and GLP-1 for people living with type 2 diabetes to assist individuals in obtaining the prescription drugs they are prescribed, and it will collaborate with physicians, insurers, and health systems to facilitate patient access to Mounjaro.
  • Stevanato Group together with Owen Mumford to expedite the Aidaptus auto-injector's manufacturing process and also provide pharmaceutical clients with pre-filled syringes so they may administer the finished product to patients.

Author Credits:  Radhika Gupta, Shivam Bhutani

  • Report ID: 3511
  • Published Date: Nov 14, 2023
  • Report Format: PDF, PPT

Frequently Asked Questions (FAQ)

Rising cases of rheumatoid arthritis and the growing government initiatives to increase awareness are the major factors driving the growth of the market.

The market size of Auto-injectors is anticipated to attain a CAGR of 17% over the forecast period, i.e., 2024-2036.

The major players in the market are Scandinavian Health Ltd., AbbVie, Inc., Amgen, Owen Mumford, Ypsomed, Biogen Idec, Mylan N.V., Pfizer, Inc., Sanofi, and Stevanato Group.

The anaphylaxis segment is anticipated to garner the largest market size by the end of 2036 and display significant growth opportunities.

The market in the North American region is projected to hold the largest market share by the end of 2036 and provide more business opportunities in the future.
Auto-Injector Market Report Scope

FREE Sample Copy includes market overview, growth trends, statistical charts & tables, forecast estimates, and much more.

 Request Free Sample Copy

Have questions before ordering this report?

Inquiry Before Buying